KAISERAUGST, Switzerland, March 8, 2017 /PRNewswire/ --
(Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )
DSM Nutritional Products and Evonik Nutrition & Care will each hold a 50% share in the joint venture and co-own the production facility, which will be built at an existing site of Evonik and is expected to come on stream in 2019. The joint venture plans to invest around US$ 200 million in the facility (USD 100 million by each party over circa 2 years). The initial annual production capacity will meet roughly 15% of the total current annual demand for EPA and DHA by the salmon aquaculture industry. The set-up of the joint venture, to be named Veramaris and headquartered in The Netherlands, will be finalized subject to regulatory approvals and other customary closing conditions.
Evonik's and DSM's highly concentrated algal oil is a high value and pure source that will enable the animal nutrition industry to keep up with the increasing demand for these two essential omega-3 fatty acids without endangering fish stocks, contributing to healthy animal nutrition as well as to the ecological balance and biodiversity of the oceans.
The text of the full press release can be found at http://www.dsm.com and http://www.evonik.com
For more information: DSM Nutritional Products Herman Betten tel. +31(0)45-5782017 e-mail [email protected] Evonik Industries Matthias Ruch tel.: +49(0)201-177-3348 e-mail: [email protected]
Video: http://mma.prnewswire.com/media/475939/DSM_and_Evonik.pdf
SOURCE Royal DSM
Advertisement
- Breakthrough for animal nutrition to reduce impact on ocean resources and making it more sustainable
- Commercial-scale facility for algal oil for salmon aquaculture and pet food to be built in the United States
- Further develop and produce a high value algal oil with a natural balance of EPA and DHA
Advertisement
(Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )
DSM Nutritional Products and Evonik Nutrition & Care will each hold a 50% share in the joint venture and co-own the production facility, which will be built at an existing site of Evonik and is expected to come on stream in 2019. The joint venture plans to invest around US$ 200 million in the facility (USD 100 million by each party over circa 2 years). The initial annual production capacity will meet roughly 15% of the total current annual demand for EPA and DHA by the salmon aquaculture industry. The set-up of the joint venture, to be named Veramaris and headquartered in The Netherlands, will be finalized subject to regulatory approvals and other customary closing conditions.
Evonik's and DSM's highly concentrated algal oil is a high value and pure source that will enable the animal nutrition industry to keep up with the increasing demand for these two essential omega-3 fatty acids without endangering fish stocks, contributing to healthy animal nutrition as well as to the ecological balance and biodiversity of the oceans.
The text of the full press release can be found at http://www.dsm.com and http://www.evonik.com
For more information: DSM Nutritional Products Herman Betten tel. +31(0)45-5782017 e-mail [email protected] Evonik Industries Matthias Ruch tel.: +49(0)201-177-3348 e-mail: [email protected]
Video: http://mma.prnewswire.com/media/475939/DSM_and_Evonik.pdf
SOURCE Royal DSM
